March 18, 2020 NIAID Funding News
Read this full edition online at http://www.niaid.nih.gov/
Feature Articles
NIH Posts Guidance on Closures and Cancellations Related to COVID-19
Review NIH instruction for researchers on practical matters like late applications, salary, stipends, clinical trials, travel, and conference grants, as they relate to closures and cancellations in response to COVID-19.
Opportunities and Resources
Propose projects to establish proof-of-concept or preclinical development of candidate universal influenza vaccines that protect against both influenza A-type and influenza B-type viruses.
Complementary to NIAID’s drive to develop a universal flu vaccine is our push to better understand the dynamics and drivers of influenza transmission among humans.
NIAID will fund centers that use 3D models derived from human stem cell or tissue to replicate host-pathogen interactions observed in natural infections.
Develop and assess novel candidate vaccines for their ability to induce protective immune responses, and to select promising candidates for preclinical development in appropriate animal models.
Receive funding support to address robustness, sustainability, reusability, and scalability of existing biomedical research software tools and workflows of recognized scientific value.
In The News
We sincerely appreciate the time and effort contributed by fiscal year 2019 members of NIAID peer review groups and Advisory committees.
When you begin your next application, you may need to choose between FORMS-E and FORMS-F based on the application due date you are targeting.
BEI Resources is prioritizing and fast-tracking all SARS-CoV-2 registrations. For such requests, BEI anticipates a 24- to 72-hour registration turn-around time.
NIH's Office of Laboratory Animal Welfare encourages institutional animal care and use committees at assured institutions to begin using the 2020 American Veterinary Medical Association Guidelines for the Euthanasia of Animals.
Advice Corner
NIH policies around resource sharing are critical for ensuring the rigor and reproducibility of NIH-funded research, so take a moment to refresh your knowledge of what NIH requires.
Reader Questions
New Funding Opportunities
- PAR-20-139, Investigator-Initiated Extended Clinical Trial (R01, Clinical Trial Required)
- RFA-AI-20-028, Partnerships for Countermeasures Against Select Pathogens (R01, Clinical Trials Not Allowed)
- PA-20-135, Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
- RFA-AI-20-015, Engineering Immunity to HIV-1 Through Next Generation Vaccines (R61/R33, Clinical Trial Not Allowed)
- RFA-AI-20-016, Harnessing Natural Killer (NK) Cells To Prevent, Control, or Eradicate HIV (R01, Clinical Trial Not Allowed)
- RFA-AI-20-010, Advancing Vaccine Science To Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (R01, Clinical Trial Not Allowed)
- PAS-20-121, Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21, Clinical Trial Not Allowed)
- PAR-20-125, Native American Research Centers for Health (NARCH) (S06, Clinical Trial Optional)
- PAR-20-120, Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19, Clinical Trial Not Allowed)
Find other announcements at NIAID Opportunities & Announcements.
Send suggestions or comments to deaweb@niaid.nih.gov.
.png)
No hay comentarios:
Publicar un comentario